DK1227810T3 - Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer - Google Patents

Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer

Info

Publication number
DK1227810T3
DK1227810T3 DK00978553T DK00978553T DK1227810T3 DK 1227810 T3 DK1227810 T3 DK 1227810T3 DK 00978553 T DK00978553 T DK 00978553T DK 00978553 T DK00978553 T DK 00978553T DK 1227810 T3 DK1227810 T3 DK 1227810T3
Authority
DK
Denmark
Prior art keywords
fatty acid
inhibition
cpt
malonyl coa
fas
Prior art date
Application number
DK00978553T
Other languages
Danish (da)
English (en)
Inventor
Craig A Townsend
Francis P Kuhajda
Ellen S Pizer
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of DK1227810T3 publication Critical patent/DK1227810T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Epoxy Compounds (AREA)
DK00978553T 1999-11-12 2000-11-13 Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer DK1227810T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16476899P 1999-11-12 1999-11-12
US16476599P 1999-11-12 1999-11-12

Publications (1)

Publication Number Publication Date
DK1227810T3 true DK1227810T3 (da) 2006-10-23

Family

ID=26860829

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00978553T DK1227810T3 (da) 1999-11-12 2000-11-13 Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer

Country Status (12)

Country Link
US (1) US20020187534A1 (fr)
EP (1) EP1227810B8 (fr)
JP (1) JP2003513920A (fr)
KR (4) KR20090130151A (fr)
AT (1) ATE330598T1 (fr)
AU (3) AU784495B2 (fr)
CA (1) CA2391277A1 (fr)
DE (1) DE60028996T2 (fr)
DK (1) DK1227810T3 (fr)
ES (1) ES2267587T3 (fr)
PT (1) PT1227810E (fr)
WO (1) WO2001034145A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4564714B2 (ja) * 2000-11-27 2010-10-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
WO2003037323A2 (fr) * 2001-10-26 2003-05-08 MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie Inhibiteurs de l'oxydation des acides gras pour la prophylaxie et le traitement des maladies liees a un dysfonctionnement mitochondrial
MXPA04007556A (es) 2002-02-08 2005-12-05 Univ Johns Hopkins Med Estimulacion de cpt-1 como medio para reducir peso.
CN101633650A (zh) * 2002-07-01 2010-01-27 法斯根有限责任公司 新化合物、包含该化合物的药物组合物及该化合物的应用方法
KR20050111573A (ko) * 2002-10-31 2005-11-25 파스젠, 엘엘씨. 지방산 신타제 억제제에 의한 암 발생 억제 방법
CA2515368A1 (fr) 2003-02-13 2004-08-26 Luciano Rossetti Regulation de la prise alimentaire et de la production de glucose par modulation des niveaux d'acyl-coa gras de chaine longue dans l'hypothalamus
CA2534816A1 (fr) 2003-06-12 2004-12-23 Evan Newell Systemes et procedes de traitement de maladies inflammatoires et proliferatives humaines et de lesions au moyen d'inhibiteurs du metabolisme des acides gras et/ou d'inhibiteurs glycolytiques
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
ITMI20040230A1 (it) * 2004-02-12 2004-05-12 Defiante Farmaceutica Lda Composti ad attivita' antitumorale
JP2008539238A (ja) * 2005-04-28 2008-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド 治療用二機能性化合物
JP2008543734A (ja) 2005-05-02 2008-12-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド 脂肪酸代謝および解糖の阻害を提供する化合物の組み合わせ、または二官能性化合物を用いるヒトの炎症性および増殖性疾患を処置するためのシステムおよび方法
US20090202569A1 (en) * 2006-04-07 2009-08-13 Tetsuo Mashima Prophylactic/Therapeutic Agent for Cancer
WO2008106796A1 (fr) * 2007-03-08 2008-09-12 University Health Network Induction d'apoptose et inhibition de prolifération cellulaire par modulation de l'activité carnitine palmitoyltransférase 1c
US8410150B2 (en) 2007-03-09 2013-04-02 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
US20090053804A1 (en) * 2007-07-27 2009-02-26 Vesta Therapeutics, Inc. Methods of reducing intracellular fats from mammalian cells
CA2694724C (fr) * 2007-08-01 2017-09-12 University Health Network Inhibiteurs cycliques de la carnitine palmitoyltransferase et traitement anticancereux
US8394377B2 (en) 2008-02-21 2013-03-12 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
WO2010008554A2 (fr) 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Procédés et produits pour traiter des maladies prolifératives
JP5317919B2 (ja) * 2009-10-05 2013-10-16 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6895890B2 (ja) 2015-02-10 2021-06-30 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊ 抗体
CA3040637C (fr) * 2016-10-17 2023-02-28 Keio University Agent d'elimination de cellules souches indifferenciees, et procede associe
EP3956663A1 (fr) * 2019-04-15 2022-02-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Procédé de profilage du métabolisme énergétique d'une population de cellules
CN113604573A (zh) * 2021-09-14 2021-11-05 北京大学第三医院（北京大学第三临床医学院） 一种使用至少八种脂肪酸代谢关键酶基因检测方法以及试剂盒
CN113549702A (zh) * 2021-09-14 2021-10-26 北京大学第三医院（北京大学第三临床医学院） 一种人脂肪酸代谢关键酶基因检测方法以及试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
KR100325766B1 (ko) * 1992-07-24 2002-07-27 더 존스 홉킨스 유니버시티 암치료를위한지방산합성억제제를함유하는약학조성물
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Also Published As

Publication number Publication date
EP1227810B8 (fr) 2006-08-16
AU1600701A (en) 2001-06-06
AU2009227836A1 (en) 2009-11-05
WO2001034145A1 (fr) 2001-05-17
AU784495B2 (en) 2006-04-13
EP1227810A1 (fr) 2002-08-07
ES2267587T3 (es) 2007-03-16
EP1227810B1 (fr) 2006-06-21
US20020187534A1 (en) 2002-12-12
KR20090130151A (ko) 2009-12-17
CA2391277A1 (fr) 2001-05-17
DE60028996T2 (de) 2007-02-08
PT1227810E (pt) 2006-11-30
JP2003513920A (ja) 2003-04-15
ATE330598T1 (de) 2006-07-15
DE60028996D1 (de) 2006-08-03
KR20090031957A (ko) 2009-03-30
KR20020060736A (ko) 2002-07-18
AU2006203005A1 (en) 2006-08-10
KR20070106648A (ko) 2007-11-02

Similar Documents

Publication Publication Date Title
DK1227810T3 (da) Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer
Tseng et al. Inhibition of MDA‐MB‐231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation‐mediated p21WAF1/CIP1 expression
Anastasiou Tumour microenvironment factors shaping the cancer metabolism landscape
Morris et al. Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning
Vriend et al. The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome
Mullen et al. Progress in the development of fatty acid synthase inhibitors as anticancer targets
Yang et al. What has passed is prolog: new cellular and physiological roles of G6PD
Izzo et al. The bidirectional relationship between cancer epigenetics and metabolism
Gogebakan et al. Role of propolis on tyrosine hydroxylase activity and blood pressure in nitric oxide synthase-inhibited hypertensive rats
MA27609A1 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
TW200716678A (en) Administration of HCV protease inhibitors in combination with food to improve bioavailability
ATE455550T1 (de) Verwendung eines extraktes aus angelica sinensis als wachstumsinhibitor von krebszellen in der tumortherapie
Li et al. LFG-500 inhibits the invasion of cancer cells via down-regulation of PI3K/AKT/NF-κB signaling pathway
DE602005015319D1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
ATE487475T1 (de) Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer
Coronel-Hernández et al. Aberrant metabolism as inductor of epigenetic changes in breast cancer: therapeutic opportunities
Rothmeier et al. The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis
Lange et al. Hydropersulfides are endogenous antioxidants that inhibit ferroptosis
NO20020829D0 (no) Ny anvendelse av docetaxel for behandling av hepatoma
Wang et al. Apigenin inhibits human SW620 cell growth by targeting polyamine catabolism
EP2633856A3 (fr) Inhibiteurs de lyase de citrate d'ATP pour le traitement du cancer
EA200500958A1 (ru) Дейтерированные производные катехоламина, а также лекарственные средства, содержащие эти соединения
Shatanawi et al. Arginase inhibition suppresses breast cancer cell proliferation
Kashyap et al. Efficacy of selinexor is dependent on IκB-α expression and NF-kb deactivation in multiple myeloma cells
최종근 et al. Comparative Modeling of Human Tyrosinase-an Important Target for Developing Skin Whitening Agents